Losing Weight RX Publishes 2026 GLP-1 Dose-Titration and Cost-Per-Milligram Open Dataset
A 198-row pharmacoeconomic study quantifies how recurring platform membership dues and high-dose surcharges alter annual Semaglutide and Tirzepatide patient expenditure across six titration steps.
Dallas, TX - November 11, 2026-- Losing Weight RX has released a new open-access pharmacoeconomic dataset and statistical report examining real-world patient expenditure per active milligram of Semaglutide and Tirzepatide across 52-week clinical titration schedules. The 198-row dataset evaluates 33 distinct outpatient access pathways spanning cash retail pharmacy pens, local weight management clinics, subscription-club telehealth platforms, and all-inclusive flat-rate online programs.

Sterile multi-dose vials arranged in ascending concentration sequence for pharmacoeconomic titration analysis.
Standard clinical weight management protocols begin at low introductory weekly doses so gastrointestinal tolerance can develop gradually before escalating to full therapeutic maintenance tiers. For weekly Semaglutide protocols, clinicians typically initiate therapy at 0.25 mg per week during Month 1 before advancing through 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg maintenance levels. Dual-receptor Tirzepatide schedules similarly progress from 2.5 mg weekly up to 15 mg weekly over six four-week intervals.
According to the Losing Weight RX audit, many digital clinics advertise low introductory teaser rates for Month 1 while adding mandatory monthly club fees of $75 to $149 or imposing $100 to $150 monthly surcharges once weekly dosages cross intermediate thresholds. Because patients spend approximately three-quarters of a full 52-week treatment year at upper maintenance strengths, introductory promotional pricing systematically understates real household expenditure.
By normalizing total 12-month patient billing—including intake consultations, monthly membership dues, cold-chain shipping charges, injection supplies, and dose-tier escalations—against cumulative milligrams dispensed over 52 weeks, the dataset establishes a standardized cost-per-milligram benchmark for healthcare consumers and benefits analysts. Full methodology, machine-readable CSV tables, and archival Digital Object Identifier documentation are available through the Losing Weight RX Dose-Titration Open Dataset Hub.
| Access Pathway Category | Typical Monthly Structure | Estimated 52-Week Total | Dose-Escalation Penalty |
|---|---|---|---|
| Cash Retail Branded Pens | $995–$1,120/mo list price | $11,940–$13,440/yr | High fixed retail list cost |
| Local In-Person Med-Spa Clinics | $450–$695/mo tiered | $5,400–$8,340/yr | +$100–$200/mo at upper doses |
| Membership-Club Telehealth Apps | $79–$145 club fee + drug bill | $3,588–$5,340/yr | Separate recurring platform dues |
| Flat-Rate All-Inclusive Online Care | $49/mo Sema · $99/mo Tirz | $588–$1,188/yr | $0 fee · $0 dose surcharge |
"Evaluating weight management programs solely by their first-month promotional price obscures what households actually pay once maintenance dosing begins in Month 4 and beyond," stated the Losing Weight RX Pharmacoeconomics Research Desk. "Publishing open row-level cost-per-milligram tables allows patients and independent researchers to audit 52-week total cost of care before committing to non-refundable multi-month contracts."
Key statistical findings in the accompanying 2026 GLP-1 Dose-Titration Pharmacoeconomic Audit show that recurring membership fees account for 24 percent to 38 percent of annual out-of-pocket spending on hybrid subscription platforms. Across upper maintenance tiers, cost per active milligram varies more than sevenfold between tiered subscription clinics and flat-rate physician networks. By contrast, flat-rate protocols that maintain $49 per month for compounded Semaglutide and $99 per month for compounded Tirzepatide across every prescribed strength reduce median 52-week household spending by more than 80 percent compared to neighborhood cash clinics.
All dataset files, variable dictionaries, percentile tables, and statistical summaries are published under an open public attribution license and mirrored across three independent open-science repositories for permanent public verification. Consumers, health journalists, and benefits researchers can inspect the complete archive and model personalized 12-month titration schedules at Losing Weight RX Open Research Datasets.

Precision calibration instruments alongside clinical titration vial tiers.